Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

BACKGROUND: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine approved for emergency use with robust efficacy and immunogenicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Gálvez, Nicolás MS, Pacheco, Gaspar A, Schultz, Bárbara M, Melo-González, Felipe, Soto, Jorge A, Duarte, Luisa F, González, Liliana A, Rivera-Pérez, Daniela, Ríos, Mariana, Berrios, Roslye V, Vázquez, Yaneisi, Moreno-Tapia, Daniela, Vallejos, Omar P, Andrade, Catalina A, Hoppe-Elsholz, Guillermo, Iturriaga, Carolina, Urzua, Marcela, Navarrete, María S, Rojas, Álvaro, Fasce, Rodrigo, Fernández, Jorge, Mora, Judith, Ramírez, Eugenio, Gaete-Argel, Aracelly, Acevedo, Mónica L, Valiente-Echeverría, Fernando, Soto-Rifo, Ricardo, Weiskopf, Daniela, Grifoni, Alba, Sette, Alessandro, Zeng, Gang, Meng, Weining, González-Aramundiz, José V, Johnson, Marina, Goldblatt, David, González, Pablo A, Abarca, Katia, Bueno, Susan M, Kalergis, Alexis M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2022
Materias:
Immunology and Inflammation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596164/
https://www.ncbi.nlm.nih.gov/pubmed/36226829
http://dx.doi.org/10.7554/eLife.81477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596164/
https://www.ncbi.nlm.nih.gov/pubmed/36226829
http://dx.doi.org/10.7554/eLife.81477

Ejemplares similares